Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Real-World Data Highlights Heart Benefits of Diabetes Drugs Semaglutide and Tirzepatide
S
Shotlee
Health & Wellness Team
4 min read
Preparing your Shotlee experience
New research indicates that semaglutide and tirzepatide, drugs used for managing type 2 diabetes, exhibit heart-protective effects in real-world settings, mirroring findings from clinical trials. The study highlights the cardiovascular benefits these medications offer to patients in everyday clinical practice.
Clinical data from real-world scenarios indicates that the GLP-1 receptor agonists semaglutide and tirzepatide are effective in managing blood sugar and weight, and also demonstrate heart-protective effects that align with the outcomes observed in clinical trials involving diverse patient populations.
A recent study published in Nature Medicine compared major adverse cardiovascular events (MACE) between glucagon-like peptide-1 (GLP-1) receptor agonists and comparators, evaluating real-world estimates against randomized trial data to inform clinical decision-making.
Adults diagnosed with type 2 diabetes are at a greater risk of myocardial infarction and stroke. Glucose-lowering medications can influence weight, blood pressure, and lipid levels, raising questions about their cardiovascular effects in routine clinical care. While randomized controlled trials provide strong evidence, they might not fully represent the older, multimorbid patient populations commonly seen in primary care settings.
Therefore, there is a need for evidence reflecting routine practice, while addressing the limitations of claims-based data, namely the potential omission of lifestyle factors like diet, smoking, or exercise. Health tracking apps like Shotlee can help monitor these lifestyle factors and their impact on diabetes management.
Researchers designed five active-comparator, new-user cohort studies utilizing three major U.S. claims databases: Medicare Parts A, B, and D (2018-2020), Optum Clinformatics Data Mart (2018-February 2025), and Merative MarketScan (2018-2023). These datasets contain de-identified longitudinal information on diagnoses, prescriptions, procedures, and healthcare usage across various populations.
The study was conducted in three phases: emulation of the SUSTAIN-6 and SURPASS-CVOT trials, expansion to real-world cohorts, and a direct comparison of tirzepatide and semaglutide. Participants included adults with type 2 diabetes and obesity, categorized by cardiovascular risk, including established cardiovascular disease, NYHA class II-III heart failure, or chronic kidney disease.
The primary endpoint was MACE, encompassing all-cause mortality, myocardial infarction, or stroke, assessed over 52 weeks. Propensity-score matching (1:1) was applied to balance treatment groups, and risk estimates were generated using Kaplan-Meier curves, Cox proportional hazards models, and fixed-effects meta-analysis. Concordance with randomized trials was evaluated using predefined benchmarks.
Benchmarking analyses showed strong agreement with reference trials. In the SURPASS-CVOT emulation (tirzepatide vs dulaglutide), the hazard ratio for MACE was 0.83 (95% CI, 0.69-1.01), compared to 0.92 (95% CI, 0.83-1.01) in the trial. Similarly, the SUSTAIN-6 emulation (semaglutide vs sitagliptin) reproduced trial-aligned estimates, except for all-cause mortality, leading to methodological refinements that emphasized myocardial infarction and stroke endpoints.
In routine-care populations, semaglutide reduced the 1-year risk of myocardial infarction or stroke to 1.5% compared to 1.7% with sitagliptin (HR, 0.82; 95% CI, 0.74-0.91). For tirzepatide versus dulaglutide, MACE risk was 1.4% versus 1.8% (HR 0.87; 95% CI, 0.75-1.01), consistent across risk groups. The head-to-head comparison of tirzepatide versus semaglutide indicated equivalent cardiovascular outcomes (HR 1.06; 95% CI, 0.95-1.18).
Secondary outcomes demonstrated that semaglutide reduced myocardial infarction (HR 0.81) and stroke (HR 0.84) compared to sitagliptin. Tirzepatide was shown to be non-inferior to dulaglutide regarding mortality, myocardial infarction, and stroke. Both GLP-1 agents showed a positive impact on composite heart-failure outcomes, with both semaglutide and tirzepatide reducing hospitalization or urgent visits.
Stratified analyses based on age, sex, SGLT2 inhibitor co-use, and cardiovascular risk showed no significant heterogeneity, supporting the external validity of the findings. Semaglutide showed a numerically lower MACE, while tirzepatide showed favorable heart failure profiles. However, limitations of claims data require mindful interpretation of causal inferences.
Semaglutide reduced MACE compared to sitagliptin in real-world care, and tirzepatide demonstrated cardiovascular effectiveness comparable to both dulaglutide and semaglutide. These findings are consistent with randomized trial evidence, reinforcing confidence that the observed benefits extend beyond controlled settings. GLP-1 receptor agonists support glycemic and weight management, while also providing significant cardiovascular protection for patients with type 2 diabetes. The findings support broader application of GLP-1 therapies to reduce cardiovascular risk in routine practice.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from News-Medical.net
View Original Article
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨